Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with ...

Linda Marban; President, Chief Executive Officer, Director; Capricor Therapeutics Inc ...

RBC Capital analyst Luca Issi maintained a Buy rating on Lexeo Therapeutics, Inc. (LXEO – Research Report) on November 13 and set a price ...

D.T. is now enjoying a new chapter of his life following his quick recovery from a heart transplant performed at Hue Central ...

Q3 2024 Earnings Call Transcript November 7, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.34, expectations were $-1.37. Operator: Good morning and welcome to ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

The company has decided to advance two new wholly-owned pipeline drugs, AOC 1086 and AOC 1072, targeting two rare genetic ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients ...

An advanced robotic system at The Hospital for Sick Children (SickKids) is changing the way physicians and scientists ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE ... The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The ...